Preimplantation Genetic Diagnosis (PGS/PGD)

On July 25, 1978, the first baby, Louise Brown, was born from a Reproductive Technology/IVF. The field of Reproductive Medicine is continually changing, as evidenced by the utilization of Intracytoplasmic Sperm Injection (ICSI), culturing embryos to Blastocyst, and utilizing genetic evaluation of embryos prior to implantation PGD/PGS.

PGD consists of two categories: 1) Preimplantation Genetic Screening (PGS) – evaluation of chromosome abnormalities like Down’s Syndrome 2) Preimplantation Genetic Diagnosis (PGD) – looking for specific gene abnormalities like Cystic Fibrosis.

Studies show that there four high risk groups of patients who have a greater likelihood for chromosome abnormalities (Aneuploidy): 1) Women with advanced maternal age (AMA) > 38years old, 2) Women with recurrent pregnancy loss (RPL), 3) Women who fail 2 or more IVF cycles (FC) and 4) Men with severe male factor (MF) < 1 million motile sperm. In each of these groups, 70%-100% of the embryos may be abnormal. Thus proceeding with PGS helps to determine which embryo to transfer.

The process is done either at the day 3 (cleavage) stage where a single cell is removed and tested or the day 5 (blastocyst) stage where several cells are removed and tested. Embryo transfer is done only with those embryos that have normal chromosomes.

Coastal Fertility Center has pioneered the use of PGD/PGS in Southern California and continues to be a leader in the field. It is our hope that we can provide valuable information to patients in an effort to allow them to make appropriate choices.